Table 2.
Common name | Systematic name | Enrichment |
---|---|---|
myo51 | SPBC2D10.14c | 4.17 (4.62, 3.71) |
myo2 | SPCC645.05c | 3.13 (2.63, 3.61) |
SPAC1250.02 | 2.93 (2.95, 2.92) | |
myo1 | SPBC146.13c | 2.74 (3.06, 2.42) |
SPAC56F8.06c*** | 2.22 (2.10, 2.36) | |
rng2 | SPAC4F8.13c | 2.04 (2.00, 2.08) |
myo3: myp2 | SPAC4A8.05c | 2.04 (2.63, 1.36) |
myo52 | SPCC1919.10c | 2.02 (1.84, 2.20) |
SPCC794.02*** | 2.00 (1.85, 2.15) | |
SPCC18.12c*** | 1.47 (1.20, 1.72) | |
Fractions containing immunopurified Rng3 were used for immunoprecipitation with antibodies against a ribosomal RNA, and the immunoprecipitates were analysed using DNA microarrays. The enrichment levels were normalized to those of the small nuclear RNA U3 (SPNCRNA.03) in the immunoprecipitate. The 10 most enriched mRNAs are shown. mRNAs encoding myosin heavy chains are shown in bold. Those RNAs marked with stars are enriched in control immunoprecipitations (cells not expressing TAP-tagged proteins) and are likely to represent false positives. None of the myosin RNAs was enriched in control experiments in which the second immunoprecipitation was carried out with anti-Myc antibodies. The enrichment column shows the average enrichment and the numbers in parentheses show the values for each of the two independent experiments. Probes for ribosomal RNAs on the microarrays showed strong signals in the immunoprecipitation with ribosomal RNA antibodies, but were not detectable above background in the negative control (data not shown). mRNA, messenger RNA; TAP, tandem affinity purification. |